Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis
Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.
Authors
- Esin Oktay
- Bilgin Demir (ORCID: https://orcid.org/0000-0003-4380-9419)
- Merve Turan (ORCID: https://orcid.org/0000-0003-4021-6095)
- Sabri BARUTÇA
- Sernaz Uzunoğlu (ORCID: https://orcid.org/0000-0001-5387-8309)
- Gamze Gokoz-Dogu
- Sait Kitaplı (ORCID: https://orcid.org/0000-0002-1143-1864)
- Özgür Tanriverdi
- Gökhan Çolak (ORCID: https://orcid.org/0000-0002-3802-461X)
- Taliha Guclu
- İsmail Bayrakci
- Ali Alkan
Institutions
- Trakya University (TR)
- Pamukkale University (TR)
- Adnan Menderes University (TR)
- Muğla University (TR)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1159/000550484
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00